Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes
Nimisha Chaturvedi(Alstom (France)), Jacques Fellay(SIB Swiss Institute of Bioinformatics), Stefan Zeuzem(Goethe University Frankfurt), John G. McHutchison(Gilead Sciences (United States)), G. Mani Subramanian(Pacific Biosciences (United States)), Diana M. Brainard(Gilead Sciences (United States)), Hongmei Mo(Gilead Sciences (United States)), Evguenia S. Svarovskaia(University of Miami), Anu Osinusi(Gilead Sciences (United States))
Cited by 19
Related Papers
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
|The Lancet. Gastroenterology & hepatology|2016|2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k